The first official guidelines for implantable mechanical circulatory support (MCS) were published in 2013 by the International Society for Heart and Lung Transplantation (ISHLT).
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Mechanical circulatory assistance
May 2, 2023
An interview with the winner of the 2022 Resident Video Competition.
May 2, 2023
This is the winning video in the 8th Annual Resident Video Competition.
April 25, 2023
CTSNet held a joint webinar with ERAS Cardiac Society on April 22, 2023 to provoke professional discussion on the topic, "Enhanced Recovery After Surgery: Improving Outcomes in Patients Requiring Mechanical Circulatory Support." This webinar was moderated by
April 21, 2023
Mitral regurgitation (MR) is often seen in patients having a left ventricular assist device (LVAD) implanted. A comparison was done between LVAD patients from the EUROMACS registry with either none-to-mild or moderate-to-severe MR prior to implantation.
March 31, 2023
Since granular single-center data is lacking for the SynCardia total artificial heart, this study reported outcomes in 100 TAH recipients in a single high-volume center. The study found that 61 percent of patients underwent successful transplant while 39 percent died on TAH support.
March 28, 2023
This single institution study compared outcomes of children
February 12, 2023
This guideline on acute mechanical circulatory support covers medical and surgical treatment of cardiogenic and pulmonary shock, management of patients supported with temporary mechanical circulatory support devices, complications, special populations, as well as palliative care, social and ethical dilemmas.
February 9, 2023
The "Contemporary Approaches to Transplantation and Mechanical Life Support" program was led by chairpersons Anna Reed, Abbas Ardehali, Ankit Bharat, and Espeed Khoshbin. View the recording of this session!
January 20, 2023
Researchers conducted a literature analysis to weigh the benefits and risks of using Impella versus ECMO for use in cases of cardiogenic shock.